TheraSphere HUD For Treatment of Unresectable Hepatocellular Carcinoma (HCC)

CompletedOBSERVATIONAL
Enrollment

183

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

April 1, 2021

Study Completion Date

April 1, 2021

Conditions
Hepatocellular Carcinoma
Interventions
OTHER

TheraSphere HUD

TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.

Trial Locations (1)

40202

University of Louisville Hospital / Norton Hospital, Louisville

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

MDS Pharma Services

INDUSTRY

lead

University of Louisville

OTHER